Ms. Paddock’s representative transactions include:
- Teva Pharmaceuticals, in its sale of its specialty global women’s health business for a combined value of $2.5 billion, including sale of Paragard® business to CooperSurgical for $1.1 billion, ex-U.S. women’s health business to CVC Capital Partners for $703 million, and Plan B One-Step® franchise to Foundation Consumer Healthcare for $675 million
- bluebird bio in connection with its $1 billion collaboration with Medigene to develop T cell receptor-based immunotherapies
- Ampersand Capital Partners and 1315 Capital in their acquisition of Genoptix, Inc., a provider of comprehensive testing solutions in hematology and solid tumor molecular profiling, from Novartis Pharmaceuticals Corporation
- Brammer Bio in its acquisition of a biologics manufacturing facility from Biogen
- Teva Pharmaceuticals, in its $40.5 billion acquisition of Allergan’s (fka Actavis/Watson) Global Generic Pharmaceuticals Business
- Hikma Pharmaceuticals, in its sale of certain generic pharmaceutical products to Renaissance Pharma
- Lupin, in connection with exclusive collaboration and license agreement with Monosol regarding development and commercialization of innovative drug products and new platform technologies
- Teva Pharmaceuticals, in connection with patent license and settlement agreements related to settlements of various brand and generic pharmaceutical patent litigation matters
- Fresenius Kabi, in connection with patent license and settlement agreements related to settlements of various pharmaceutical patent litigation matters
- Licensing of intellectual property assets from research institutions
Ms. Paddock is a member of the Boston Bar Association and the Women’s Bar Association.
Prior to joining Goodwin, Ms. Paddock was an associate at Kenyon & Kenyon, where her practice concentrated on patent litigation and counseling in the pharmaceutical, medical device, and biotechnology fields.
While in law school, Ms. Paddock was named a Paul J. Liacos and Edward F. Hennessey Scholar and was a member of the American Journal of Law & Medicine.
Prior to law school, Ms. Paddock worked for four years as a chemical engineer for Hoffmann-LaRoche, where she managed projects involving the transfer and scale up of technology for the manufacture of pharmaceuticals and fine chemicals from research and development facilities in Switzerland to production sites in the United States.